European Firms Develop Tunisian Pharma Model
A coalition of European companies announced its successful development of a transformative model for manufacturing active pharmaceutical ingredients (APIs). This advances Tunisia's ability to continuously upgrade and produce pharmaceutical materials locally, thereby reducing reliance on large centralized factories. The project aims to develop factories for the continuous production of APIs, representing an important step towards strengthening drug security and health sovereignty in Tunisia—especially in the wake of logistical and health crises. The coalition includes European companies such as Novalyx, Alisophile, and De Dietrich, which are working to improve supply chain resilience and bring production closer to the local market. This enhances the country’s capacity to meet its long-term healthcare needs.
Notice: This Is an AI-Generated Summary
Comments (0)